Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Geoffrey Liu
Based on 4 articles published since 2009
(Why 4 articles?)
||||

Between 2009 and 2019, Geoffrey Liu wrote the following 4 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Sensitive tumour detection and classification using plasma cell-free DNA methylomes. 2018

Shen, Shu Yi / Singhania, Rajat / Fehringer, Gordon / Chakravarthy, Ankur / Roehrl, Michael H A / Chadwick, Dianne / Zuzarte, Philip C / Borgida, Ayelet / Wang, Ting Ting / Li, Tiantian / Kis, Olena / Zhao, Zhen / Spreafico, Anna / Medina, Tiago da Silva / Wang, Yadon / Roulois, David / Ettayebi, Ilias / Chen, Zhuo / Chow, Signy / Murphy, Tracy / Arruda, Andrea / O'Kane, Grainne M / Liu, Jessica / Mansour, Mark / McPherson, John D / O'Brien, Catherine / Leighl, Natasha / Bedard, Philippe L / Fleshner, Neil / Liu, Geoffrey / Minden, Mark D / Gallinger, Steven / Goldenberg, Anna / Pugh, Trevor J / Hoffman, Michael M / Bratman, Scott V / Hung, Rayjean J / De Carvalho, Daniel D. ·Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. · Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada. · Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. · Genome Technologies, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. · UMR_S 1236, Univ Rennes 1, Inserm, Etablissement Fran├žais du sang Bretagne, Rennes, France. · Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA. · Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. · Fred Litwin Centre for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. · Department of Surgery, Toronto General Hospital, Toronto, Ontario, Canada. · Department of Computer Science, University of Toronto, Toronto, Ontario, Canada. · Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada. rayjean.hung@lunenfeld.ca. · Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. rayjean.hung@lunenfeld.ca. · Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. ddecarv@uhnresearch.ca. · Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. ddecarv@uhnresearch.ca. ·Nature · Pubmed #30429608.

ABSTRACT: The use of liquid biopsies for cancer detection and management is rapidly gaining prominence

2 Article BRM polymorphisms, pancreatic cancer risk and survival. 2016

Segedi, Maja / Anderson, Laura N / Espin-Garcia, Osvaldo / Borgida, Ayelet / Bianco, Teresa / Cheng, Dangxiao / Chen, Zhuo / Patel, Devalben / Brown, M Catherine / Xu, Wei / Reisman, David / Gallinger, Steven / Cotterchio, Michelle / Hung, Rayjean / Liu, Geoffrey / Cleary, Sean P. ·Department of Surgery, University of British Columbia, Vancouver, BC, Canada. · Princess Margaret Cancer Centre-University Health Network-Ontario Cancer Institute, University of Toronto, Toronto, ON, Canada. · Mount Sinai Hospital-Lunenfeld Research Institute, Toronto, ON, Canada. · Medical Oncology, University of Florida, Gainesville, FL. · Prevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada. · Princess Margaret Cancer Centre-University Health Network-Ontario Cancer Institute, University of Toronto, Toronto, ON, Canada. Geoffrey.Liu@uhn.ca. ·Int J Cancer · Pubmed #27487558.

ABSTRACT: Variant alleles of two promoter polymorphisms in the BRM gene (BRM-741, BRM-1321), create MEF2D transcription binding sites that lead to epigenetic silencing of BRM, the key catalytic component of the SWI/SNF chromatin remodeling complex. BRM suppression can be reversed pharmacologically.(1) Our group and others have reported associations with lung, head and neck, hepatocellular cancer risk,(1-3) and with lung and esophageal cancer prognosis (ASCO 2013; abstract 11057 & 4077). Herein, we assessed risk and survival associations with pancreatic cancer. A provincial population-based case-control study was conducted with 623 histologically confirmed pancreatic adenocarcinoma cases and 1,192 age/gender distribution-matched controls.(4) Survival of cases was obtained through the Ontario Cancer Registry. Logistic and Cox proportional hazard regression models were fitted, adjusting for relevant covariates. Median age was 65 y; 52% were male; Stage I (8%), II (55%), III (14%), IV (23%); 53% after curative resection, 79% after chemotherapy; and 83% had died. In the risk analysis, adjusted odds ratios (aOR) were 1.01 (95% CI: 0.1-2.0) and 0.96 (95% CI: 0.7-1.3) for the homozygotes of BRM-741 and BRM-1321, respectively; aOR of double-homozygotes was 1.11 (95% CI: 0.80-1.53), compared to the double-wildtype. For the survival analysis, adjusted hazard ratios (aHR) were 2.19 (95% CI: 1.9-2.5) for BRM-741 and 1.94 (95% CI: 1.7-2.2) for BRM-1321, per unit increase in variant alleles. Compared with the double-wildtype, aHR for carrying no, one, and two double-homozygotes were 2.14 (95% CI: 1.6-2.8), 4.17 (95% CI: 3.0-5.7), 8.03 (95% CI: 5.7-11.4), respectively. In conclusion, two functional promoter BRM polymorphisms were not associated with pancreatic adenocarcinoma risk, but are strongly associated with survival.

3 Article The association of family history of cancer and medical history with pancreatic cancer risk. 2014

Fehringer, Gordon / Gallinger, Steven / Borgida, Ayelet / Zhang, Li Rita / Adams, Laura / Liu, Geoffrey / Hung, Rayjean J. ·Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, Department of Surgery, University of Toronto, Toronto, Ontario, Canada Familial Gastrointestinal Cancer Registry, Digestive Diseases Clinical Research Centre, Joseph and Wolf Lebovic Centre, Mount Sinai Hospital Toronto, Ontario, Canada Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada University Health Network, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada Department of Medicine, University of Toronto, Toronto, Ontario, Canada Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital, Toronto, Ontario, Canada rayjean.hung@lunenfeld.ca. ·Pancreas · Pubmed #24921205.

ABSTRACT: -- No abstract --

4 Article Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk. 2013

Jang, Ji-Hyun / Cotterchio, Michelle / Borgida, Ayelet / Liu, Geoffrey / Gallinger, Steven / Cleary, Sean P. ·Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Prevention and Cancer Control, Cancer Care Ontario, Toronto, Ontario, Canada. ·Mol Carcinog · Pubmed #23908141.

ABSTRACT: Mitotic regulator genes have been associated with several cancers, however little is known about their possible association with pancreatic cancer. Smoking and family history are the strongest risk factors for this highly fatal disease. The main purpose of this study was to determine if polymorphisms of mitotic regulator genes are associated with pancreatic cancer and whether they modify the association between cigarette smoking and pancreatic cancer risk. A population-based case-control study was conducted in Ontario with 455 pathology-confirmed pancreatic cancer cases and 893 controls. Cigarette smoking history was collected using questionnaires and DNA obtained from blood samples. Genotypes were determined by mass-spectrometry. Odds ratio estimates were obtained using multivariate logistic regression. Interactions between genetic variant and smoking were assessed using stratified analyses and the likelihood ratio statistic (significance P < 0.05). Variants of MCPH1, FYN, APC, PRKCA, NIN, TopBP1, RIPK1, and SNW1 were not independently associated with pancreatic cancer risk. A significant interaction was observed between pack-years and MCPH1-2550-C > T (P = 0.02). Compared to never smokers, individuals with 10-27 pack-years and MCPH1-2550-CC genotype were at increased risk for pancreatic cancer (MVOR = 2.49, 95% confidence interval [95% CI]: 1.55, 4.00) as were those with >27 pack-years and MCPH1-2550-TC genotype (MVOR = 2.42, 95% CI: 1.45, 4.05). A significant interaction was observed between smoking status and TopBP1-3257-A > G (P = 0.04) using a dominant model. Current smokers with the TopBP1-3257 A allele were at increased risk for pancreatic cancer (MVOR = 2.55, 95% CI: 1.77, 3.67). MCPH1-2550-C > T and TopBP1-3257-A > G modify the association between smoking and pancreatic cancer. These findings provide insights into the potential molecular mechanisms behind smoking-associated pancreatic cancer.